Key result
In STEMI patients not receiving reperfusion therapy, fondaparinux reduced the 30-day risk of death or myocardial re-infarction compared to usual care (12.2% vs 15.1%; HR 0.80; 95% CI 0.65-0.98).
Why the study?
Does fondaparinux reduce death or myocardial re-infarction in STEMI patients not receiving reperfusion treatment?
RCT (n=2,867)
Stratified by indication for unfractionated heparin
Does fondaparinux reduce death or myocardial re-infarction in STEMI patients not receiving reperfusion treatment?
Hazard Ratio: 0.8 (95% CI 0.65–0.98)
Absolute Event Rate: 12.2% vs 15.1%
In STEMI patients not receiving reperfusion therapy, fondaparinux reduces the risk of death or re-infarction at 30 days without increasing severe bleeding or stroke compared to placebo or unfractionated heparin.
No takes yet. Share an insight, caveat, or question.
Supports fondaparinux in reperfusion-ineligible STEMI; extends randomized evidence to this high-risk subgroup.
Oldgren et al. (2007) conducted an RCT in ST-segment elevation acute myocardial infarction (STEMI) (n=2,867). Fondaparinux vs. Usual care (placebo or unfractionated heparin) was evaluated on Death or myocardial re-infarction at 30 days (HR 0.80, 95% CI 0.65-0.98). In STEMI patients not receiving reperfusion therapy, fondaparinux reduced the 30-day risk of death or myocardial re-infarction compared to usual care (12.2% vs 15.1%; HR 0.80; 95% CI 0.65-0.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: